Neurophysiologic changes during estrogen augmentation in perimenopausal depression

Maturitas

Volumn 56, Issue 1, 2007, Pages 54-60

  Morgan, Melinda L ^a   Cook, Ian A ^a   Rapkin, Andrea J ^b   Leuchter, Andrew F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antidepressant medication; Depression; Estrogen; Estrogen augmentation; Menopause; QEEG

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CONJUGATED ESTROGEN; FLUOXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BRAIN PERFUSION; CLIMACTERIUM; CLINICAL ARTICLE; ELECTROENCEPHALOGRAPHY; ESTROGEN THERAPY; FEMALE; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; INVOLUTIONAL DEPRESSION; MAJOR DEPRESSION; MEMORY DISORDER; MENOPAUSAL SYNDROME; MENSTRUAL IRREGULARITY; MOOD DISORDER; NEUROPHYSIOLOGY; NIGHT SWEAT; QUANTITIATIVE ELECTROENCEPHALOGRAPHY; REMISSION; VAGINAL DRYNESS;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROENCEPHALOGRAPHY; ESTROGEN REPLACEMENT THERAPY; FEMALE; FRONTAL LOBE; HUMANS; MIDDLE AGED; PERIMENOPAUSE;

EID: 33845481397     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.05.010     Document Type: Article

References (39)

1. Soares C.N., Poitras J.R., Prouty J., Alexander A.B., Shifren J.L., and Cohen L.S. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry 64 (2003) 473-479
2. Rasgon N.L., Altshuler L.L., Fairbanks L.A., et al. Estrogen replacement therapy in the treatment of major depressive disorder in perimenopausal women. J Clin Psychiatry 63 Suppl 7 (2002) 45-48
3. Tam L.W., and Parry B.L. Does estrogen enhance the antidepressant effects of fluoxetine?. J Affect Disord 77 (2003) 87-92
4. Liu P., He F.F., Bai W.P., et al. Menopausal depression: comparison of hormone replacement therapy and hormone replacement therapy plus fluoxetine. Chin Med J 117 (2004) 189-194
5. Morgan M.L., Cook I.A., Rapkin A.J., and Leuchter A.F. Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study. J Clin Psychiatry 66 (2005) 774-780
6. Amin Z., Canli T., and Epperson C.N. Effect of estrogen-serotonin interaction on mood and cognition. Behav Cogn Neurosci Rev 4 (2005) 43-58
7. Rubinow D.R., Schmidt P.J., and Roca C.A. Estrogen-serotonin interaction: implications for affective regulation. Biol Psychiatry 44 (1998) 839-850
8. Saletu B., Brandstatter N., Metka M., et al. Hormonal syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas 23 (1996) 91-105
9. Kwon J.S., Youn T., and Jung H.Y. Right hemisphere abnormalities in major depression: quantitative electroencephalographic finding before and after treatment. J Affect Disord 40 (1996) 169-173
10. Drevets W.C., Bogers W., and Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropharmacol 12 (2002) 527-544
11. Cook I.A., Leuchter A.F., Morgan M.L., et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 27 (2002) 20-131
12. Davies J., Keith R., Lloyd K.R., Jones I.K., Barnes A., and Pilowsky L.S. Changes in regional cerebral blood flow with venlafaxine in the treatment of major depression. Am J Psychiatry 160 (2003) 374-376
13. Davidson R.C., Irwin W., Anderle M.J., and Kalin N.H. The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 160 (2003) 64-75
14. Fu C.H., Williams S.C., Cleare A.J., et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry 61 (2004) 877-889
15. Kalia M. Neurobiological basis of depression: an update. Metabolism 54 Suppl (2005) 24-27
16. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., and Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res 90 (1999) 125-140
17. Spitzer R. Structural clinical interview for DSM-IV (1994), State Psychiatric Institute, New York
18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6 (1967) 278-296
19. Soules M.R., Sherman S.L., Parrott E., et al. Executive summary: stages of reproductive aging workshop (STRAW). Climacteric 4 (2001) 267-272
20. Cook I.A., O'Hara R., Uijtdehaage S.H., Mandelkern M., and Leuchter A.F. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr Clin Neurophysiol 107 (1998) 408-414
21. Leuchter A.F., Cook I.A., Witte E.A., Morgan M.L., and Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159 (2002) 122-129
22. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 57 (2002) 357-384
23. McEwen B., Alves S., Bulloch K., and Weiland N.G. Ovarian steroids and the brain: implications for cognition and aging. Neurology 48 (1997) 8-15
24. Blier P., and Montigny C. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychopharmacology 21 2S (1999) 91-98
25. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13 (2003) 57-66
26. Moses E., Drevets W.C., Smith G., et al. The effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 48 (2000) 854-860
27. Kugaya A., Epperson C.N., Zoghbi S., et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 60 (2003) 1522-1524
28. Wihlback A.C., Sundstrom-Poromaa I., Allard P., Mjorndal T., Spigset O., and Backstrom T. Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstet Gynecol 98 (2001) 450-457
29. Drevets W.C., Bogers W., and Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropharmacol 12 (2002) 527-544
30. Brody A.L., Saxena S., Stoessel P., et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 58 (2001) 631-640
31. Nobler M.S., Sackeim H.A., Prohovnik I., et al. Regional cerebral blood flow in mood disorders. Part III. Treatment and clinical response. Arch Gen Psychiatry 51 (1994) 884-897
32. Martinot J.L., Hardy P., Feline A., et al. Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry (1990) 1313-1317
33. Austin M.P., Dougall N., Ross M., et al. Single photon emission tomography with 99mTc-exametazime in major depression and the pattern of brain activity underlying the psychotic/neurotic continuum. J Affect Disord 26 (1992) 31-43
34. Bonne O., and Krausz Y. Pathophysiological significance of cerebral perfusion abnormalities in major depression-trait or state marker?. Eur Neuropsychopharmacol 7 (1997) 225-233
35. Bonne O., Krausz Y., Shapira B., et al. Increased cerebral blood flow in depressed patients responding to electroconvulsive therapy. J Nucl Med 37 (1996) 1075-1080
36. Vlassenko A., Sheline Y.I., Fischer K., and Mintun M.A. Cerebral perfusion response to successful treatment of depression with different serotoninergic agents. J Neuropsychiatry Clin Neurosci 16 (2004) 360-363
37. Teneback C.C., Nahas Z., Speer A.M., et al. Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS. J Neuropsychiatry Clin Neurosci 11 (1999) 426-435
38. Leuchter AF, Cook IA, Hunter A, Morgan ML, McGrouther C, Abrams M. Functional brain changes associated with remission in major depressive disorder. In Poster presented at the Society of Biological Psychiatry Annual Scientific Convention. Atlanta, Georgia, 21-26 May; 2005.
39. Modena M.G., Sismondi P., Mueck A.O., et al. New evidence regarding hormone replacement therapies is urgently required: transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 52 (2005) 1-10